Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
The FDA's approval for Novartis' atrasentan in the kidney disease IgAN means Chinook Therapeutics investors will see a $160 million payday. It also means more competition is on the way for Travere Therapeutics.
The FDA's approval for Novartis' atrasentan in the kidney disease IgAN means Chinook Therapeutics investors will see a $160 million payday. It also means more competition is on the way for Travere Therapeutics.
